Weifeng Ding | Pancreatic Cancer | Best Researcher Award

Posted on by Pencis

Prof. Dr. Weifeng Ding | Pancreatic Cancer | Best Researcher Award

Affiliated Hospital of Nantong University | China

Author Profile

Scopus

📚 EARLY ACADEMIC PURSUITS

Dr. Ding Weifeng embarked on his academic journey with a strong foundation in medical laboratory science. His dedication to excellence and a deep interest in clinical research paved the way for advanced education, culminating in a Ph.D. His academic rigor was further enriched during his tenure as a Senior Visiting Scholar at the University of Texas Health Science Center (UTH) in the United States, where he gained international exposure and expertise.

🏆 PROFESSIONAL ENDEAVORS

Currently, Dr. Ding serves as the Deputy Director of the Department of Clinical Laboratory at the Affiliated Hospital of Nantong University and the Deputy Director of the Department of Laboratory Medicine at Nantong University. He holds dual roles as Chief Technologist, Associate Professor, and Master’s Supervisor, combining practical expertise, teaching, and mentorship in his field.

His professional career reflects significant recognition as a high-level talent under Jiangsu Province's "333" Project, a leading figure in Nantong City's "226" Project, and a key young medical talent in Jiangsu Province.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON PANCREATIC CANCER

Dr. Ding's research expertise spans medical laboratory science, with significant contributions in:

  • Advancing laboratory diagnostics.
  • Innovating approaches to translational medicine and molecular techniques.

He has successfully led three National Natural Science Foundation projects, a China Postdoctoral Science Foundation project, and seven provincial and municipal research projects. These projects demonstrate his ability to bridge clinical applications and theoretical research.

🌍 IMPACT AND INFLUENCE

Dr. Ding has gained widespread recognition for his contributions to scientific research, including the:

  • Third Prize of Jiangsu Medical Science and Technology Award
  • Second Prize of Nantong Science and Technology Progress Award
  • Nantong Youth Science and Technology Award

His achievements underscore his impact on the fields of clinical practice and scientific innovation.

📈 ACADEMIC CITATIONS AND SCHOLARLY IMPACT

Dr. Ding has authored nearly 30 SCI-indexed papers as the first or corresponding author, reflecting his leadership and originality in research. Furthermore, his five Chinese invention patents attest to his contributions to technological advancements in medical diagnostics.

🌟 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Ding’s dedication to medical laboratory science has left a lasting legacy in education, innovation, and clinical practice. He actively fosters the next generation of professionals through mentorship and collaboration while pushing the frontiers of translational medicine and diagnostic technology.

In the years ahead, he is expected to:

  • Strengthen collaborations across global institutions.
  • Expand research projects in cutting-edge medical technologies.
  • Continue mentoring aspiring professionals in the medical laboratory field.

🌐 ENGAGEMENT IN ACADEMIC ORGANIZATIONS

Dr. Ding is actively involved in professional communities:

  • Standing Committee Member of the Abdominal Tumor Comprehensive Rehabilitation Branch, China Medical Education Association.
  • Committee Member of the Translational Medicine Professional Committee, Jiangsu Immunology Society.
  • Member of the Clinical Molecular Group, Jiangsu Medical Association Laboratory Medicine Branch.

📑NOTABLE PUBLICATIONS 

"Combined ultrasound endoscopy-guided fine-needle aspiration with DNA methylation of SHOX2 and RASSF1A genes to enhance the auxiliary diagnostic precision of pancreatic cancer" 

  • Authors: Shan, Y. , Teng, Y. , Guan, C. , Ding, W. , Zhang, J.
  • Journal: Heliyon
  • Year: 2024

"DNA methylation modulates epigenetic regulation in colorectal cancer diagnosis, prognosis and precision medicine" 

  • Authors: Ye, J., Zhang, J., Ding, W.
  • Journal: Exploration of Targeted Anti-tumor Therapy
  • Year: 2024

"Retraction Note: Targeting of colorectal cancer growth, metastasis, and anti-apoptosis in BALB/c nude mice via APRIL siRNA (Molecular and Cellular Biochemistry" 

  • Authors: Wang, J. , Ding, W. , Sun, B. , Shi, G. , Wang, H.
  • Journal: Molecular and Cellular Biochemistry
  • Year: 2023

"DNA hypermethylation contributes to colorectal cancer metastasis by regulating the binding of CEBPB and TFCP2 to the CPEB1 promoter " 

  • Authors: Shao, K. , Pu, W. , Zhang, J. , Zhang, Z. , Ding, W.
  • Journal: Clinical Epigenetics
  • Year: 2021

"Targeted Bisulfite Sequencing Reveals DNA Methylation Changes in Zinc Finger Family Genes Associated With KRAS Mutated Colorectal Cancer" 

  • Authors: Pu, W. , Qian, F. , Liu, J. , Ju, S. , Ding, W.
  • Journal: Frontiers in Cell and Developmental Biology
  • Year: 2021

Gang liu | Cancer | Best Researcher Award

Posted on by Pencis

Prof Gang liu | Cancer | Best Researcher Award

Gansu Provincial Center for Disease Control and Prevention | China

Author Profile

Scopus

Gang Liu: Pioneer in Radiobiology and Preventive Medicine ⚛️

EARLY ACADEMIC PURSUITS 🎓

Gang Liu began his academic journey at Lanzhou University, where he pursued a PhD in preventive medicine. His graduation in 1997 marked the beginning of a career dedicated to understanding the impacts of radiation on health. His academic training in preventive medicine provided the foundation for his future contributions to radiobiology and public health, particularly in the context of disease control and prevention.

PROFESSIONAL ENDEAVORS 🏢

After obtaining his PhD, Gang Liu embarked on a distinguished career at the Gansu Provincial Center for Disease Control and Prevention. His professional focus has been on the intersection of radiobiology, immunology, and tumor screening. In 2019, his registration as a health physicist signaled a significant milestone. He became the technical lead for a groundbreaking study on low-dose dose-effect relationships, a critical area in radiation therapy and safety. His expertise in radiation protection and therapy has earned him a prominent position within the medical research community.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER🧬

Gang Liu's research primarily revolves around radiobiology and radiation protection in therapy. His technological advancements in biological dose estimation are considered cutting-edge within China and recognized internationally. One of his significant contributions was revising the 2011 IAEA Manual based on findings from his studies on radiological sensitivity and dose rates. This revision, coupled with his publications in the FASEB Journal, has made Liu a leading figure in radiation science. His work in chromosomal aberration analysis and developing noninvasive techniques for early-stage cancer screening underscores his innovative approach to medical research.

IMPACT AND INFLUENCE 🌍

Gang Liu's influence extends beyond national borders. His research on radiological sensitivity and dose rates, especially in the context of cancer screening and radiation therapy, has set new benchmarks in the field. The international recognition of his work, particularly his advancements in biological dose estimation and contributions to global radiation protection protocols, underscores his importance in radiobiology. His work is used by institutions worldwide to improve radiation safety standards and enhance cancer diagnostic techniques.

ACADEMIC CITATIONS 📚

His pioneering research has been published in prestigious journals such as the FASEB Journal, one of the top international platforms for scientific contributions. The citations of his work in radiological sensitivity, chromosomal aberration analysis, and cancer screening techniques reflect his deep impact on the scientific community, with his methods influencing both practical applications in healthcare and further research.

LEGACY AND FUTURE CONTRIBUTIONS 🔬

Gang Liu’s legacy will likely be defined by his leadership in advancing radiation protection technology and cancer screening techniques. As an innovator in radiological health, his influence will continue to grow through future contributions to radiation therapy safety, noninvasive cancer detection, and international health standards. His ongoing work in exploring new methods for biological dose estimation will further establish his standing as a key figure in the evolution of radiation medicine.

NOTABLE PUBLICATIONS 📑

"Study of Low-Dose Radiation Workers Ionizing Radiation Sensitivity Index and Radiation Dose-Effect Relationship" 

  • Authors: Liu, G., Zhang, R., Li, Y., Liu, Y.Y., Zhang, X.
  • Journal: Health Physics
  • Year: 2022

"Revision of cytogenetic dosimetry in the IAEA manual 2011 based on data about radio-sensitivity and dose-rate findings contributing" 

  • Authors:Liu, G.
  • Journal: FASEB Journal
  • Year: 2022

"Thyroid dose assessments due to inhalation of 131I for nuclear medicine workers"

  • Authors: Liu, G., Li, Y., Zhang, H., Niu, L.M., Zhang, R.
  • Journal: Frontiers in Public Health
  • Year: 2022

"Study of Indicators for Early and Rapid Diagnosis of Radiation Injury Is the Most Important in Patients With Cancer During Radiotherapy"

  • Authors: Liu, G., Niu, L.-M., Wang, L.-Q., Liu, Y.-Y., Zhang, R.
  • Journal: Dose-Response
  • Year: 2020

"Chromosomal aberration analysis: Novel noninvasive techniques for early-stage cancer screening"

  • Authors: Liu, G.
  • Journal: Clinica Chimica Acta
  • Year: 2024